Zortix
Sign in
Everything said about
NKTR
+ Watchlist
0
Ideas · 30d
1
Episodes
4.0
Avg depth
1
Ideas · all time
The conversation · most recent first
10 JUN10 JUNYET ANOTHER VALUE PODCAST · 07:15
Nectar Therapeutics sell-off seen as overdone
"The guest argued that Nectar's recent stock decline is an overreaction to transient headwinds like litigation and perceived competition, leaving the underlying asset undervalued."
MIXEDIn depth · 4/5
MENTIONS & DEPTH REFLECT PODCAST DISCUSSION VOLUME · NOT A RATING, FORECAST, OR RECOMMENDATION